[1] |
Rosanova MT, Mussini MS, Arias AP, et al. Epidemiological features and risk factors for mortality in Pseudomonas aeruginosa bacteremia in children[J]. Arch Argent Pediatr,2019,117(2):128-131.
|
[2] |
董方, 王艳, 刘锡青, 等. 2009-2015年北京儿童医院临床分离细菌的分布及耐药性监测[J]. 中国感染与化疗杂志,2017,17(1):61-70.
|
[3] |
Pfaller MA, Flamm RK, Duncan LR, et al. Antimicrobial activity of tigecycline and cefopperazone/sulbactam tested against 18 386 Gram-negative arganisms from Europe and the Asia Pacific region (2013-3014)[J]. Diagn Microbiol Infect Dis,2017,88(2)177-183.
|
[4] |
Miyoshi-akiyamat T, TAada T, Ohmagari N, et al. Emer-gence and spread of Epidemic multidrug-resistant Pseudomonas earuginosa[J]. Genome Biol Evol,2017,9(12):3238-3245.
|
[5] |
Thong KL, Lai MY, Teh C SJ, et al. Simultaneous detection of methicillin-resistant Staphylococcus aureus, Aeinetobaeter baumannii, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa by multiplex PCR[J]. Trop Biomed,2011,28(1):21-31.
|
[6] |
Parkins MD, Gregson DB, Pitout JD, et al. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection[J]. Infection,2010,38(1):25-32.
|
[7] |
Soothill J. Use of bacteriophages in the treatment of Pseudomonas aeruginosa infections[J]. Expert Rev Anti Infect Ther,2013,11(9):909-915.
|
[8] |
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Twenty-Seventh Informational Supplement,2017:M100S. 27th Edition.
|
[9] |
任伟, 龙晓玲, 周涛, 等. 儿童铜绿假单胞菌脓毒症14例临床分析[J]. 临床儿科杂志,2016,34(9):674-676.
|
[10] |
Alaga L, Mediavilla JD, Cobo F. A clinical index predicting mortality with Pseudomonas aeruginosa bacteraemia[J]. J Med Microbiol,2002,51(7):615-619.
|
[11] |
王真, 刘青, 蒋慧杨, 等. 儿童急性淋巴细胞白血病中性粒细胞缺乏伴发热单中心血流感染病原菌分析[J]. 循证儿科杂志,2019,14(3):186-190.
|
[12] |
Dantas RC, Ferreira ML, Gontijo-Filho PP, et al. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome[J]. J Med Microbiol,2014,63(12): 1679-1687.
|
[13] |
Hu Y, Li L, Li W, et al. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies[J]. Int J Antimicrob Agents,2013,42(6):492-496.
|
[14] |
Kim YJ, Jun YH, Kim YR, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy[J]. BMC Infect Dis,2014,14:161.
|
[15] |
Gargouri L, Maaloul I, Kamoun T, et al. Ecthyma gangrenosum: A manifestation of community-acquired Pseudomonas aeruginosa septicemia in three infants[J]. Arch Pediatr,2015,22(6):616-620.
|
[16] |
Yan W, Li W, Mu C, et al. Ecthyma gangrenosum and multiple nodules: cutaneous manifestations of Pseudomonas aeruginosa sepsis in a previously healthy infant[J]. Pediatr Dermatol,2011,28(2):204- 205.
|
[17] |
高娅, 李娇, 杜鑫珂, 等. 54例儿童铜绿假单胞菌血流感染临床特点及耐药分析[J]. 临床儿科杂志,2019,37(2):118-122.
|
[18] |
周益平, 张育才. 铜绿假单胞菌脓毒症的临床特征与救治策略[J]. 中国小儿急救医学,2011,18(4):375-377.
|
[19] |
Viola L, Langer A, Pulitano S, et al. Serious Pseudomonas aeruginosa infection in health children: Case report and review of the literature[J]. Pediatr Int,2006,48(3):330-333.
|
[20] |
何时军, 金益梅, 黄爱蓉, 等. 儿童社区获得性铜绿假单胞菌致感染性休克九例分析[J]. 中华儿科杂志,2008,46(5):333-338.
|
[21] |
Lodise TP Jr, Patel N, Kwa A, et al. Predietors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections:impact of delayed appropriate antibiotic seleetion[J]. Antimicrob Agents Chemother,2007,51(10):3510-3515.
|
[22] |
Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome[J]. Clin Infect Dis,2003,37(6):745-751.
|
[23] |
Kim HS, Park BK, Kim SK, et al. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study[J]. BMC Infect Dis,2017,17(1):500.
|
[24] |
Koichi Kitagawa K, Shigemura K, Yamamichi F, et al. Bacteremia complicating urinary tract infection by Pseudomonas aeruginosa: Mortality risk factors[J]. Int J Urol,2019,26(3):358-362.
|
[25] |
陈愉生, 吴春兰, 李鸿茹, 等. 铜绿假单胞菌血流感染56例临床分析[J]. 中国感染与化疗杂志,2016,16(5):529-535.
|
[26] |
Thirumalmuhu K, Devarajan B, Prajna L, et al. Mechanisms of fluoroquinolone and aminoglycoside resistance in keratitisassociated Pseudomonas aeruginosa[J]. Microb Drug Resist,2019,25(6):813-823.
|
[27] |
Barbier F, Andremont A, Wolff M, et al. Hospital-acquired pneumonia and ventilator associated pneumonia: recent advances in epidemiology and management[J]. Curr Opin Pulm Med,2013,19(3):216-228.
|
[28] |
Saxena P, Joshi Y, Rawat K, et al. Biofilms: architecture, resistance, quorum densing and control mechanisms[J]. Indian J Microbiol,2019,59(1):3-12.
|
[29] |
Correia S, Poeta P, Hebraud M, et al. Mechanisms of quinolone action and resistance:where do we stand?[J]. J Med Microbiol,2017,66(5): 551-559.
|
[30] |
Hammer KL, Justo JA, Bookstaver PB, et al. Differential effect of prior β-lactams and fluoroquinolones on risk of bloodstream infections secondary to Pseudomonas aeruginosa[J]. Diagn Microbiol Infect Dis,2017,87(1):87-91.
|
[31] |
Paulsson M, Granrot A, Ahl J, et al. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study[J]. Eur J Clin Microbiol Infect Dis,2017,36(7):1187-1196.
|